MAZZUCCHI, SONIA
 Distribuzione geografica
Continente #
NA - Nord America 1.411
EU - Europa 780
AS - Asia 158
AF - Africa 64
OC - Oceania 3
SA - Sud America 1
Totale 2.417
Nazione #
US - Stati Uniti d'America 1.386
IT - Italia 264
SE - Svezia 212
DE - Germania 112
CN - Cina 82
BG - Bulgaria 66
AT - Austria 43
CI - Costa d'Avorio 41
SG - Singapore 37
GB - Regno Unito 30
VN - Vietnam 25
CA - Canada 22
SN - Senegal 17
FI - Finlandia 9
FR - Francia 8
IE - Irlanda 7
NL - Olanda 7
RU - Federazione Russa 7
NG - Nigeria 6
BE - Belgio 5
HK - Hong Kong 5
IN - India 5
PL - Polonia 5
AU - Australia 3
ES - Italia 2
IR - Iran 2
MX - Messico 2
AR - Argentina 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
EE - Estonia 1
JP - Giappone 1
NO - Norvegia 1
TR - Turchia 1
Totale 2.417
Città #
Woodbridge 196
Fairfield 168
Chandler 139
Ann Arbor 101
Ashburn 86
Houston 84
Seattle 84
Wilmington 69
Sofia 66
New York 64
Cambridge 56
Milan 55
Serra 42
Abidjan 41
Vienna 41
Frankfurt am Main 39
Florence 38
Princeton 35
Lawrence 30
Medford 29
Beijing 28
Pisa 25
Trieste 23
Bremen 21
Guangzhou 21
Ottawa 19
Des Moines 18
Dakar 17
Dong Ket 11
Dearborn 10
San Diego 10
Los Angeles 9
Nanjing 8
Lagos 6
London 6
Massa E Cozzile 6
Norwalk 6
Nürnberg 6
Brussels 5
Redwood City 5
Warsaw 5
Falls Church 4
Galway 4
Hong Kong 4
Lancaster 4
Shanghai 4
Vecchiano 4
Vicopisano 4
Indiana 3
Moscow 3
Paris 3
Rho 3
Amsterdam 2
Barcelona 2
Burlington 2
Calgary 2
Canosa Di Puglia 2
Changsha 2
Cuauhtémoc 2
Harbin 2
Hebei 2
Hefei 2
Kostroma 2
Manchester 2
Massarosa 2
Maynooth 2
Medolago 2
Nanchang 2
Ogden 2
Pune 2
Rome 2
Shenyang 2
Tianjin 2
Utrecht 2
Xian 2
Acton 1
Ames 1
Baotou 1
Bergen 1
Boston 1
Boydton 1
Brescia 1
Buenos Aires 1
Böblingen 1
Central 1
Chehalis 1
Chicago 1
Dallas 1
Dublin 1
Edinburgh 1
Grodno 1
Grosseto 1
Hamedan 1
Hangzhou 1
Hounslow 1
Izmir 1
Jiaxing 1
Jinan 1
Kilburn 1
Kingston 1
Totale 1.839
Nome #
Chronic Migraine with Medication Overuse and OnabotulinumtoxinA: Two Positive Case Reports of a Modified Injection Protocol 146
Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction 139
Social Cognition and Oxytocin in Huntington’s Disease: New Insights 128
Efficacy of a combined therapeutic approach in the management of Pisa Syndrome 118
Current treatment and future prospects of dopa-induced dyskinesias. 114
The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-na?ve patients with Parkinson's disease. 113
Antipsychotic drugs in Huntington's disease 113
Migraine features in migraineurs with and without anxiety-depression symptoms: A hospital-based study 110
Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease. 100
Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases 92
Symptomatic orthostatic tremor associated with Graves' disease. 87
Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study 86
null 86
Brain-Derived Neurotrophic Factor (BDNF) and Serotonin Transporter (SERT) in Platelets of Patients with Mild Huntington’s Disease: Relationships with Social Cognition Symptoms 83
Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up 80
Head tremor as a warning symptom of rapidly progressive syringomyelia: a case report 78
null 75
Bipolar Spectrum disorders in Parkinson's disease: a systematic evaluation 74
Plasma levels of oxidative stress markers, before and after BoNT/A Treatment, in chronic migraine 70
Automated MRI Classification in Progressive Supranuclear Palsy: a Large International Cohort Study 66
Connected speech in progressive supranuclear palsy: a possible role in differential diagnosis 62
Quantitative susceptibility mapping in atypical Parkinsonisms 58
Prevalence and clinical correlates of comorbid anxiety and panic disorders in patients with Parkinson’s disease 43
Does the Degree of Trunk Bending Predict Patient Disability, Motor Impairment, Falls, and Back Pain in Parkinson's Disease? 40
A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study 40
Supersaturation of VEP in Migraine without Aura Patients Treated with Topiramate: An Anatomo-Functional Biomarker of the Disease 40
Prevalence and impact of COVID-19 in Parkinson’s disease: evidence from a multi-center survey in Tuscany region 39
Cgrp inhibitors and oxidative stress biomarkers in resistant migraine: A real‐life study with erenumab, fremanezumab and galcanezumab 37
Neuroimaging in idiopathic adult-onset focal dystonia 36
Nigral involvement and nigrostriatal dysfunction in Huntington's disease: evidences from an MRI and SPECT study. 33
The role of synaptic biomarkers in the spectrum of neurodegenerative diseases 28
Functional gait disorders: Demographic and clinical correlations 28
Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease 12
Morphometric imaging and quantitative susceptibility mapping as complementary tools in the diagnosis of parkinsonisms 8
Data-driven clustering of combined Functional Motor Disorders based on the Italian registry 7
Perampanel as a novel treatment for subcortical myoclonus in myoclonus-dystonia syndrome 6
Totale 2.475
Categoria #
all - tutte 7.510
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.510


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201982 0 0 0 0 0 0 0 0 0 0 46 36
2019/2020398 42 15 44 24 30 50 43 40 45 31 20 14
2020/2021273 11 44 7 16 12 10 65 16 21 18 13 40
2021/2022378 9 6 5 23 73 51 13 23 34 18 27 96
2022/2023606 81 88 53 38 52 64 8 31 121 0 59 11
2023/2024341 34 33 41 37 48 87 24 19 5 13 0 0
Totale 2.475